Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Byetta effect on 24-hour heart rate in type 2 diabetes
NCT00516074Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2007
- Primary completion
- Apr 2008
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Sep 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00516074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516074.